Project Details
Description
A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94- 9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first line
| Status | Finished |
|---|---|
| Effective start/end date | 7/1/16 → 11/30/16 |
Funding
- BAYER HEALTHCARE PHARMACEUTICALS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.